Mer­ck­'s pneu­mo­coc­cal vac­cine suf­fers PDU­FA de­lay in pe­di­atric pop­u­la­tion, with Pfiz­er hot on its tail

Back in Ju­ly, Mer­ck’s pneu­mo­coc­cal vac­cine Vaxneu­vance got the seal of ap­proval from the FDA to treat adults, with an­a­lysts pre­dict­ing it could be a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.